News
May 25, 2023
TScan Therapeutics Announces Launch of Proposed Public Offering
May 24, 2023
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
May 17, 2023
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 10, 2023
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 2, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
April 10, 2023
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
March 31, 2023
TScan Therapeutics Announces CEO Transition
March 14, 2023
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 13, 2023